GLP-1 receptor agonists, which were originally developed to treat Type 2 diabetes, have been used for more than 15 years
Key Players:Agilent Technologies, AstraZeneca, AmbioPharm - A Global Peptide CDMO, Bachem, Biosynth, Corden Pharma - A Full-Service CDMO, CSBio, ChinaPeptides Co., Ltd., Eli Lilly and Company, GenScript, GSK, Merck Group, Novo Nordisk, PolyPeptide Group, Sanofi, ScinoPharm Taiwan Ltd, Thermo Fisher Scientific, TakedaPharmaceutical Nordics AB, Teva Pharmaceuticals, amo ng others
Hormonal regulation beyond insulin: Some studies suggest that semaglutide may also help rebalance reproductive hormones, contributing to improved menstrual health, reduced androgens, and better overall endocrine function
Fortune 's CFO Daily newsletter is the must-read analysis every finance professional needs to get ahead